The George Washington University
Washington D.C., District of Columbia, 20037, United States
NCT Number: NCT07808541
The goal of this clinical trial is to evaluate the impact of the Juntas Adelante intervention on awareness and use of chemoprophylaxis for HIV prevention (Pre- and Post-Exposure prophylaxis, or PrEP and PEP) among Latina Transgender Women in the Washington DC Metropolitan Area. Secondary outcomes included awareness and use of Doxy-PEP (i.e., Doxycycline for prevention of Sexually Transmitted Infections - STI), and awareness of Undetectable = Untransmittable (U=U).
The main questions are:
1. Is the Juntas Adelante intervention acceptable and feasible to implement with this population? 2. Is participating in the Juntas Adelante intervention associated with increased awareness and use of PrEP and PEP? All participants in the study will view 5 online short videos on HIV and STI prevention and will receive up to two virtual coaching sessions with a peer coach. They will also complete a brief survey after viewing each video (5 total) and three longer surveys/interviews over the course of 3 months.
Looking for future studies?
Notify Me18 year and older
Male
Interventional
Not applicable
Washington D.C., District of Columbia, 20037, United States
Using a community-based participatory research (CBPR) approach, we developed Juntas Adelante, an intervention to increase awareness and use of PrEP and PEP for HIV prevention among Latina transgender women in the DC metropolitan area. The Juntas Adelante intervention includes two components:
Participant recruitment and eligibility: Participants will be recruited via referrals from community members (i.e., members of the Community Council, other study participants). Eligibility criteria include: 1) Male sex assigned at birth, currently identifying as a woman, transgender woman, transgender, or transsexual, irrespective of gender transition stage; 2) identifying as Latina, regardless of country of birth; 3) being 18 years old or older; 4) living in the DC metropolitan area; 5) self-reporting HIV negative status at study enrollment 6) reporting having receptive anal and/or neovaginal sex with at least one cisgender man or transgender woman in the previous 12 months; 7) not currently using PrEP or report less than 3 months of use; 8) have access to a cellphone with internet capabilities, and 9) not planning to move from the DC metropolitan area in the next 12 months.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The Juntas Adelante intervention includes two components:
Time frame: "Final follow up, 3 months after last coaching session"
Our primary outcome is PrEP initiation/persistence or PEP use at the 3-month follow up, defined as the combination of any:
Time frame: Baseline survey to final follow-up 3 months after last coaching session.
Whether participant knows about PrEP for HIV prevention, evaluated by comparing baseline to 3-month follow-up surveys.
Time frame: Baseline survey to final follow-up 3 months after last coaching session.
Whether participant knows about PEP for HIV prevention, evaluated by comparing baseline to 3-month follow-up surveys.
Time frame: Baseline survey to final follow-up 3 months after last coaching session.
Whether participant knows about (awareness) or has used Doxy-PEP for STI prevention, evaluated by comparing baseline to 3-month follow-up surveys.
Time frame: Baseline survey to final follow-up 3 months after last coaching session.
Whether participant knows about Undetectable equals Untransmittable as a treatment-as-prevention message, evaluated by comparing baseline to 3-month follow-up surveys.
George Washington University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02599896
HIV Antibodies, Monoclonal Antibody, Human
Bethesda, Maryland, United States
View Trial DetailsNCT05215262
HIV Prevention, STI Prevention
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT05950828
HIV/AIDS Prevention, Pregnancy Prevention
Accord, New York, United States
View Trial DetailsNCT05952973
HIV/AIDS Prevention, Pregnancy Prevention
Accord, New York, United States
View Trial Details